Prospectus -- share offering

Financing type:  at-the-market prospectus offering

Gross proceeds:  $1,519.27 in the quarter ended March 4, 2026

Offering:  245 listed shares

Offering price:  an average price of $6.20 per listed share

Disclosure:  Refer to the prospectus supplement dated Dec. 19, 2024, and the company's news releases dated July 8, 2025, and March 12, 2026.

Delisting

Further to the completion of the ATM (at-the-market) offering, effective at the close of business on March 16, 2026, the common shares of Nervgen Pharma Corp. will be delisted from the TSX Venture Exchange at the request of the company.

The company will continue to trade on the Nasdaq Capital Market.